Jun 26, 2025 08:08AM GRI Bio's (GRI) GRI-0621 Demonstrates Encouraging Safety Results at Planned Interim 6-Week Analysis in Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis

Jun 11, 2025 06:39AM H.C. Wainwright Reiterates Buy Rating on GRI Bio, Inc. (GRI)

May 22, 2025 08:03AM GRI Bio, Inc (GRI) Presents Positive Pre-Clinical Data Demonstrating GRI-0621 Resolves Inflammation and Fibrosis in Bleomycin-Induced Fibrosis and Reiterates Promising Preliminary Phase 2a Clinical Re

May 15, 2025 08:35AM GRI Bio, Inc (GRI) Confirms GRI-0621 Phase 2a IPF Trial on Track for 6-Week Interim Data in Q2 2025 and Topline Data in Q3 2025

May 8, 2025 08:48AM GRI Bio, Inc (GRI) Reports Interim Biomarker Data Showing Positive Trend Towards Anti-Fibrotic Effect with GRI-0621

Apr 14, 2025 06:55AM H.C. Wainwright Reiterates Buy Rating on GRI Bio, Inc. (GRI)

Apr 1, 2025 11:15AM GRI Bio, Inc (GRI) Announces Pricing of $5.0 Million Public Offering

Apr 1, 2025 09:00AM GRI Bio, Inc (GRI) Reports Encouraging Interim 2-Week Safety Results from Ongoing Phase 2a Study of GRI-0621

Mar 31, 2025 08:03AM GRI Bio (GRI) Bolsters Intellectual Property Portfolio with Granting of Two Global Patents for Europe and Japan

Mar 11, 2025 08:35AM GRI Bio, Inc (GRI) regains compliance with Nasdaq rule

Feb 19, 2025 04:05PM GRI Bio, Inc (GRI) Announces 1:17 Reverse Share Split

Feb 11, 2025 04:29PM GRI Bio (GRI) approves reverse stock split, stockholders vote in favor

Nov 21, 2024 08:45AM GRI Bio, Inc (GRI) Showcases GRI-0621’s Potential to Reduce Inflammation, Type 1 Cytokines and Reduce Hepatic Fibrosis in Idiopathic Pulmonary Fibrosis

Nov 14, 2024 04:40PM GRI Bio, Inc (GRI) Files for 1.58M Share Offering by Selling Stockholders

Oct 24, 2024 08:34AM GRI Bio, Inc (GRI) Raises a Total of $13.9M in Gross Proceeds Since the Beginning of 2024

Oct 16, 2024 08:45AM GRI Bio, Inc (GRI) Presents Positive Preclinical Data Demonstrating GRI-0621’s Ability to Inhibit Invariant Natural Killer T Cell Activity

Oct 8, 2024 06:17AM Ascendiant Capital Starts GRI Bio, Inc. (GRI) at Buy

Sep 30, 2024 08:30AM GRI Bio (GRI) Granted Japan Patent for Proprietary Natural Killer T (NKT) Cell Modulators for Prevention and Treatment of Inflammatory Conditions

Sep 26, 2024 08:01AM GRI Bio, Inc (GRI) Authorized for Phase 2a Biomarker Study of GRI-0621

Jul 8, 2024 09:05AM GRI Bio, Inc (GRI) Regains Compliance with Nasdaq

Jul 2, 2024 09:06AM GRI Bio, Inc (GRI) Announces Publication of Positive Preclinical Data from Lead Program GRI-0621 in the American Journal of Respiratory and Critical Care Medicine

Jun 27, 2024 09:00AM GRI Bio, Inc (GRI) Announces Korea Patent Granted for Proprietary Natural Killer T Cell Modulators

Jun 27, 2024 08:00AM GRI Bio, Inc (GRI) Prices 2.19M Share Offering at $1.83/sh

Jun 14, 2024 08:05AM GRI Bio, Inc (GRI) Announces 1:13 Reverse Share Split

Jun 12, 2024 04:15PM Connect Biopharma (CNTB) Appoints Barry Quart as CEO, David Szekeres as President